SOLUTRANS
SOLUTRANS , the global hub for heavy and light commercial vehicles, will hold its 16th edition from 16 to 20 November 2021 in Lyon Eurexpo (France). Nearly 60,000 professionals, 1,000 exhibitors and brands are expected to attend this international event focusing on economic recovery and innovation, certified by the OICA (International Organization of Motor Vehicle Manufacturers).
This edition will showcase two major additions. Firstly, a "SOLUTRANS 4.0" hall dedicated to innovation for transport professionals. Secondly, the chance for professionals from all over the world to take part in the show remotely via the SOLUTRANS DIGITAL SHOW.
HGV manufacturers will be in attendance
The leading HGV manufacturers, such as DAF, IVECO, MAN, Mercedes, Renault Trucks, SCANIA and VOLVO will be exhibiting at SOLUTRANS. The largest bodywork manufacturers, vehicle fitters and service companies will also be present, as well as new names in the sector such as FORD TRUCKS, IRIZAR and VOLTA TRUCKS, who will be taking part for the first time in France.
SOLUTRANS 4.0, the hall of new technologies
This hall will present disruptive innovations and new names in the sector in all areas, from engineering to industry as well as IT solutions.
The objective of SOLUTRANS 4.0 is to foster the implementation of new solutions to optimize activity and overcome the challenges in the sector: energy transition, artificial intelligence, cybersecurity, recycling, etc.
Innovation gets the green light at SOLUTRANS !
All the innovations will be presented during the various award ceremonies that will take place during the trade show. The I-nnovation Awards have been further enriched this year and include a new prize: the "Digital AWARD". Also, for the fourth consecutive edition, SOLUTRANS will host the International Awards: ITOY, IVOTY, IPUA and TRUCK INNOVATION AWARD. These awards, recognized by the industry as a whole, reward the excellence of manufacturers and showcase the trends in the industrial and urban vehicle sector.
The theme of innovation will also be highlighted during the event via a broad range of conferences covering a variety of topics that respond to the challenges of the sector.
Finally, SOLUTRANS, in partnership with TotalEnergies, will be offering a new, completely redesigned and larger testing area to meet the needs of visitors and manufacturers of heavy and light commercial vehicles. The track has also been extended and re-designed with a 25 km semi-urban route to allow professionals to test the vehicles around the park.
SOLUTRANS DIGITAL SHOW: unlimited online access to the trade show
The SOLUTRANS DIGITAL SHOW, the virtual edition of the physical exhibition, will offer registered visitors, wherever they are located in the world, an interactive space where they can visit exhibitors' stands, contact their representatives and discover their new products… it’s all just click away! Two weeks before the actual trade show, registered visitors will be able to start making appointments with exhibitors and take advantage of the three additional days of opening to consult an exhibitor's offer online, thus giving them a chance to contact businesses that they wouldn’t have had time to meet during the physical edition of the trade show. They will also have access to conferences and other events, which will be broadcast live.
Discover the whole program of the SOLUTRANS 2021 trade show on solutrans.eu
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom